On Mar. 9, 2021, Oragenics announced it had entered into a material transfer agreement with Biodextris for the use of three intranasal mucosal adjuvants in the Companyﾒs Terra CoV-2 vaccine against COVID-19.

Adjuvants are added to vaccines to enhance their immunogenicity. BDX100, BDX300 and BDX301 are proteosome-based adjuvants comprised of proteins and lipopolysaccharides with improved attributes including enhanced immune response, manufacturing efficiency and the benefits of intranasal vaccine administration.